Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor

Abstract

An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated.

1 . An improving agent for dysfunction due to nerve damage, characterized in that, said agent comprising an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone as an active ingredient. 
     
     
         2 . The improving agent according to  claim 1 , wherein the nerve damage is that arising from spinal cord injury. 
     
     
         3 . The improving agent according to  claim 1 , wherein the nerve damage is amyotrophic lateral sclerosis. 
     
     
         4 . The improving agent according to  claim 3 , wherein the dysfunction due to nerve damage is motor neuron dysfunction. 
     
     
         5 . The improving agent according to any of  claim 3 , wherein the dysfunction due to nerve damage is sensory neuron dysfunction. 
     
     
         6 . The improving agent according to  claim 5 , wherein the sensory neuron dysfunction is neuropathic pain. 
     
     
         7 . The improving agent according to  claim 6 , wherein the neuropathic pain is a pain caused by allodynia or hyperalgesic reaction. 
     
     
         8 . An improving agent for neuropathic pain, characterized in that, said agent comprising an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone as an active ingredient. 
     
     
         9 . An Rho kinase activation inhibitor, characterized in that, said inhibitor comprising an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in the keratan sulfate backbone as an active ingredient. 
     
     
         10 . The improving agent according to  claim 1 , wherein the dysfunction due to nerve damage is motor neuron dysfunction. 
     
     
         11 . The improving agent according to  claim 1 , wherein the dysfunction due to nerve damage is sensory neuron dysfunction. 
     
     
         12 . The improving agent according to  claim 11 , wherein the sensory neuron dysfunction is neuropathic pain. 
     
     
         13 . The improving agent according to  claim 12 , wherein the neuropathic pain is a pain caused by allodynia or hyperalgesic reaction. 
     
     
         14 . The improving agent according to  claim 2 , wherein the dysfunction due to nerve damage is motor neuron dysfunction. 
     
     
         15 . The improving agent according to  claim 2 , wherein the dysfunction due to nerve damage is sensory neuron dysfunction. 
     
     
         16 . The improving agent according to  claim 15 , wherein the sensory neuron dysfunction is neuropathic pain. 
     
     
         17 . The improving agent according to  claim 16 , wherein the neuropathic pain is a pain caused by allodynia or hyperalgesic reaction.